A spectroscopic and molecular docking approach on the binding of TINZAPARIN SODIUM (cas 12656-11-0) with human serum albumin
-
Add time:08/16/2019 Source:sciencedirect.com
Protein bound toxins are poorly removed by conventional extracorporeal therapies. Venous thromboembolism (VTE) is a major cause of morbidity and mortality in patients with cancer. The interaction between tinzaparin, an inhibitor of angiotensin converting enzyme and human serum albumin, a principal plasma protein in the liver has been investigated in vitro under a simulated physiological condition by UV–vis spectrophotometry and fluorescence spectrometry. The intrinsic fluorescence intensity of human serum albumin was strongly quenched by tinzaparin (TP). The binding constants and binding stoichiometry can be calculated from the data obtained from fluorescence quenching experiments. The negative value of ΔG° reveals that the binding process is a spontaneous process. Thermodynamic analysis shows that the HSA-TP complex formation occurs via hydrogen bonds, hydrophobic interactions and undergoes slight structural changes as evident by far-UV CD. It indicated that the hydrophobic interactions play a main role in the binding of TP to human serum albumin. In addition, the distance between TP (acceptor) and tryptophan residues of human serum albumin (donor) was estimated to be 2.21 nm according to the Förster's resonance energy transfer theory. For the deeper understanding of the interaction, thermodynamic, and molecular docking studies were performed as well. Our docking results suggest that TP forms stable complex with HSA (Kb ∼ 104) and its primary binding site is located in subdomain IIA (Sudlow Site I). The results obtained herein will be of biological significance in pharmacology and clinical medicine.
We also recommend Trading Suppliers and Manufacturers of TINZAPARIN SODIUM (cas 12656-11-0). Pls Click Website Link as below: cas 12656-11-0 suppliers
Prev:Regular ArticleAntiangiogenic activities of bemiparin sodium, enoxaparin sodium, nadroparin calcium and TINZAPARIN SODIUM (cas 12656-11-0)
Next:TINZAPARIN SODIUM (cas 12656-11-0) for thrombosis treatment and prevention during pregnancy☆) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- PaperBinding of low molecular weight heparin (TINZAPARIN SODIUM (cas 12656-11-0)) to bovine endothelial cells in vitro08/21/2019
- Selected Topics: ToxicologyIntentional Overdose With Tinzaparin: Management Dilemmas08/20/2019
- Original ArticleThromboelastography (TEG®) demonstrates that tinzaparin 4500 international units has no detectable anticoagulant activity after caesarean section08/19/2019
- Regular ArticleWeight-adjusted dosing of tinzaparin in pregnancy☆08/18/2019
- TINZAPARIN SODIUM (cas 12656-11-0) for thrombosis treatment and prevention during pregnancy☆08/17/2019
- Regular ArticleAntiangiogenic activities of bemiparin sodium, enoxaparin sodium, nadroparin calcium and TINZAPARIN SODIUM (cas 12656-11-0)08/15/2019
-
Health and Chemical more >
-
Related Products
- Sodium 2,4-dimethylbenzenesulfonate
- SODIUM γ-FLUORO-β-HYDROXYBUTYRATE
- Sodium ((3-methoxy-1-methyl-3-oxo-1-propenyl)amino)phenylacetate
- Sodium (+)-10-camphorsulfonate
- Sodium (2-carbamoylphenoxy)acetate
- Sodium (2-methyl-4-chlorophenoxy)acetate
- Sodium (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate pentahydrate
- Sodium (C10-16)alkylbenzenesulfonate
- Sodium (R,R)-5-(2-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)propyl)-1,3-benzodioxole-2,2-
- Sodium (S)-lactate


